These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 18528186

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 5. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E, Aras G, Kucuk NO.
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 8. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [Abstract] [Full Text] [Related]

  • 9. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C, Wang X, Shao M, Zhao L, Jiawei X, Wu Z, Wang H.
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [Abstract] [Full Text] [Related]

  • 11. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin.
    van Dijk D, Plukker JT, Phan HT, Muller Kobold AC, van der Horst-Schrivers AN, Jansen L, Sluiter WJ, Brouwers AH, Links TP.
    Thyroid; 2013 Aug; 23(8):1003-9. PubMed ID: 23517405
    [Abstract] [Full Text] [Related]

  • 12. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N.
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [Abstract] [Full Text] [Related]

  • 13. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M.
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [Abstract] [Full Text] [Related]

  • 16. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M.
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [Abstract] [Full Text] [Related]

  • 17. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T, Kowalska A, Lesiak J, Młynarczyk J.
    Nucl Med Rev Cent East Eur; 2014 Jan; 17(2):87-93. PubMed ID: 25088108
    [Abstract] [Full Text] [Related]

  • 18. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Jan; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 19. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Jan; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 20. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer.
    Esteva D, Muros MA, Llamas-Elvira JM, Jiménez Alonso J, Villar JM, López de la Torre M, Muros T.
    Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.